Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 341

1.

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases.

Safaei A, Arefi Oskouie A, Mohebbi SR, Rezaei-Tavirani M, Mahboubi M, Peyvandi M, Okhovatian F, Zamanian-Azodi M.

Gastroenterol Hepatol Bed Bench. 2016 Summer;9(3):158-73. Review.

2.

Suppression of PPARγ-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis.

Yu JH, Song SJ, Kim A, Choi Y, Seok JW, Kim HJ, Lee YJ, Lee KS, Kim JW.

Sci Rep. 2016 Jul 11;6:29352. doi: 10.1038/srep29352.

3.

The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease.

Jamali R, Hatami N, Kosari F.

Hepat Mon. 2016 Apr 20;16(5):e37412. doi: 10.5812/hepatmon.37412. eCollection 2016 May.

4.
5.

Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.

Jurado-García J, Muñoz García-Borruel M, Rodríguez-Perálvarez ML, Ruíz-Cuesta P, Poyato-González A, Barrera-Baena P, Fraga-Rivas E, Costán-Rodero G, Briceño-Delgado J, Montero-Álvarez JL, de la Mata-García M.

PLoS One. 2016 Jun 14;11(6):e0155822. doi: 10.1371/journal.pone.0155822. eCollection 2016.

6.

Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

Liu X, Zhang P, Martin RC, Cui G, Wang G, Tan Y, Cai L, Lv G, Li Y.

Am J Cancer Res. 2016 May 1;6(5):1011-25. eCollection 2016.

7.

Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.

Yang KC, Hung HF, Lu CW, Chang HH, Lee LT, Huang KC.

Sci Rep. 2016 Jun 1;6:27034. doi: 10.1038/srep27034.

8.

The Natural Course of Non-Alcoholic Fatty Liver Disease.

Calzadilla Bertot L, Adams LA.

Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774. Review.

9.

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.

Cusi K.

Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21. Review.

10.

Hypoxia-inducible factors as molecular targets for liver diseases.

Ju C, Colgan SP, Eltzschig HK.

J Mol Med (Berl). 2016 Jun;94(6):613-27. doi: 10.1007/s00109-016-1408-1. Epub 2016 Apr 20. Review.

11.

Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.

Sanchez-Pareja A, Clément S, Peyrou M, Spahr L, Negro F, Rubbia-Brandt L, Foti M.

World J Gastroenterol. 2016 Apr 14;22(14):3735-45. doi: 10.3748/wjg.v22.i14.3735.

12.

Chronic hepatitis E virus infection after living donor liver transplantation via blood transfusion: a case report.

Kurihara T, Yoshizumi T, Itoh S, Harimoto N, Harada N, Ikegami T, Inagaki Y, Oshiro Y, Ohkohchi N, Okamoto H, Maehara Y.

Surg Case Rep. 2016 Dec;2(1):32. doi: 10.1186/s40792-016-0159-0. Epub 2016 Apr 8.

13.

Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A.

Int J Mol Sci. 2016 Mar 9;17(3):355. doi: 10.3390/ijms17030355. Review.

14.

Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study.

Dugum M, Hanouneh I, McIntyre T, Pai R, Aucejo F, Eghtesad B, Zein N.

Mol Clin Oncol. 2016 Mar;4(3):369-374. Epub 2016 Jan 14.

15.

Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list.

Basaranoglu M, Najjar SM, Demirbag AE, Senturk H.

World J Hepatol. 2016 Mar 8;8(7):376-84. doi: 10.4254/wjh.v8.i7.376.

16.

Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.

Wainwright P, Byrne CD.

Int J Mol Sci. 2016 Mar 11;17(3):367. doi: 10.3390/ijms17030367. Review.

17.

Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?

García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ.

World J Gastroenterol. 2016 Mar 14;22(10):2869-74. doi: 10.3748/wjg.v22.i10.2869.

18.

Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response.

Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T.

Hepat Med. 2016 Feb 22;8:9-20. doi: 10.2147/HMER.S63700. eCollection 2016. Review.

19.

Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Afonso MB, Rodrigues PM, Simão AL, Castro RE.

J Clin Med. 2016 Mar 3;5(3). pii: E30. doi: 10.3390/jcm5030030. Review.

20.

Cytoprotective role of heme oxygenase-1 in liver ischemia reperfusion injury.

Liu B, Qian JM.

Int J Clin Exp Med. 2015 Nov 15;8(11):19867-73. eCollection 2015. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk